Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

NCT01431521 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: MK-4074 200 mg
DRUG: Placebo for MK-4074
DRUG: Pioglitazone hydrochloride 30 mg
DRUG: Placebo for pioglitazone hydrochloride

Sponsor

Merck Sharp & Dohme LLC